Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Research & Development: 2010-2025

Historic Research & Development for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $607.2 million.

  • Arrowhead Pharmaceuticals' Research & Development rose 28.61% to $174.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $607.2 million, marking a year-over-year increase of 20.02%. This contributed to the annual value of $607.2 million for FY2025, which is 20.02% up from last year.
  • According to the latest figures from FY2025, Arrowhead Pharmaceuticals' Research & Development is $607.2 million, which was up 20.02% from $505.9 million recorded in FY2024.
  • In the past 5 years, Arrowhead Pharmaceuticals' Research & Development ranged from a high of $607.2 million in FY2025 and a low of $206.3 million during FY2021.
  • Moreover, its 3-year median value for Research & Development was $505.9 million (2024), whereas its average is $488.7 million.
  • Data for Arrowhead Pharmaceuticals' Research & Development shows a peak YoY soared of 60.11% (in 2021) over the last 5 years.
  • Arrowhead Pharmaceuticals' Research & Development (Yearly) stood at $206.3 million in 2021, then skyrocketed by 44.08% to $297.3 million in 2022, then rose by 18.80% to $353.2 million in 2023, then skyrocketed by 43.23% to $505.9 million in 2024, then climbed by 20.02% to $607.2 million in 2025.